Submitted by Anonymous on Wed, 01/05/2013 - 21:39.
Here's a little reality for you. Its 2013, companies aren't worth very much anymore, they cannot create growth and most are now worth more in pieces than as a chinese buffet. Thermo will be a great example of that in 5 years.
Submitted by Anonymous on Wed, 01/05/2013 - 06:33.
Yes, but their CEO can do magic with investors. Who needs a real product when you can buy scientists to get good reviews and off load the company to BD for 400 million. Buy their stock while you still can.
Submitted by Anonymous on Tue, 30/04/2013 - 20:48.
FLDM's problem is at its core technology: PDMS valve. It can only go that far. Fluidigm opens lots of new fields, yet its technology cannot achieve what it promises.
Submitted by Anonymous on Mon, 29/04/2013 - 21:58.
Nice massive stock drop today... great timing, looks like more money spend and more money made... Its pretty simple, pcr, single cell, heading towards the commodity market...
Submitted by Anonymous on Wed, 13/02/2013 - 01:17.
Haha ha fluidigm. Make more to lose more money. I think it's obvious this dog will never have its head above the water. Gajus can't wait to get back to Alaska so he can come up with more fake shit.
Submitted by Anonymous on Mon, 19/11/2012 - 22:07.
O.K, next prediction; Fluidigm will try very hard to to get bought out by BD. Go GW! Settle for nothing below $400mil. Just focus on the clueless executives and it should be easy to convince them. We paid $200 mil for our last big acquisition and its doing great at becoming the leading loss center, so adding Fluidigm too our portfolio is the next logical step.
Submitted by Anonymous on Sun, 30/09/2012 - 04:10.
Well as a customer, their sales people suck. They have no idea on how to support their customers. On the other hand, we've actually really liked the instrument and have been generating good data like crazy.
Submitted by Anonymous on Thu, 16/08/2012 - 21:56.
Wow, did I call that or what? It just announced second IPO today. GW is a genius at raising capitol, can spin a new story every time, and it never misses. Amazing! Let's wait for some fishing/sailing/bear hunting, in the eye of the storm stories to be announced soon as a press release to follow..
Submitted by Anonymous on Tue, 15/05/2012 - 17:07.
"Wow, they are the only growth story, I will but their stock now for sure!"
You need to buy a shit load more NOW !
There is no growth or buzz here... The tech is interesting, its use is not impressive and certainly not the markets they play in. Established and flat.
Submitted by Anonymous on Fri, 11/05/2012 - 19:58.
Sorry to say but AA is gone in a year, BMK is only up because there is more feet on the street and acceptance is flat. Are they gonna keep talking about single cell for 3 more years because their pipeline is empty and the BMK is one dinosaur ! You don't have a WW business if you get all wet at 10 million a quarter. Sure the progress is good but the volumes are simply anemic... simple as that.
Submitted by Anonymous on Fri, 11/05/2012 - 18:10.
BTW, following the announcement of Fluidigm's Q1 2012 earnings results, the analyst ratings on the stock are:
Leerink Swann - outperform
Piper - overwieght
Cowen - outperform
Oppenheimer - outperform
Seems like everyone is recommending to buy, not sell.
Submitted by Anonymous on Fri, 11/05/2012 - 18:05.
BofA doesn't cover Fluidigm so there is no way for them to downgrade the stock.
The analsyts that currently follow FLDM are Leerink Swann, Cowen and Company, Piper Jaffray and Oppenheimer. Deutsche Bank used to cover the stock, but their entire life science tools team jumped to ISI. They can't pick up coverage for at least 6 months (the law). Deutsche Bank hasn't yet replaced their analyst team.
Submitted by Anonymous on Wed, 15/02/2012 - 01:14.
As long as losses increase every quarter than only the revenue growth should matter. I wonder if there are other ways to further increase revenue/ losses. That would really be in the best interest of shareholders.
Submitted by Anonymous on Sat, 14/01/2012 - 18:52.
Has Fluidigm had a profitable quarter yet? They have been around for almost 13 years, so if they are "growing into a real company with a viable long term future", then they need to hit profitability.
Submitted by Anonymous on Fri, 13/01/2012 - 18:16.
Fluidigm is the only growth story in life science tools right now. By far the best life science IPO of 2011. Beat the Street estimates every quarter since they became a public company. Looking at their comparables, they are roughly flat while others are minus 30-40 percent. Look back over the string of messages here and see if any of the negatives spewed here have any truth as time has passed. None of the negatives have happened. Fluidigm is growing into a real company with a viable long term future.
Submitted by Anonymous on Fri, 18/02/2011 - 07:45.
"Very true, but if that's the case they need to lean-out operations to show profitability on just the life sci biz. No reason they shouldn't have been running in the black for the past 2 years.
Inexperienced CEO has no true operations experience. BJ/RR care only for themselves. MU/AB have been truly brilliant at creating a toxic culture.
All should move aside and let the grownups make the company a real success before time renders them irrelevant."
You speak as though you know what's going on, yet clearly have no idea of what it actually takes to run a business like this, nor any concept of how much money it takes. Any further "lean-out" of operations would render the company non-functional, although there are still one or two pseudo-academics (perhaps you are one) that should be axed. the company has a long way to go, but makes great products and has finally started to generate significant revenue.
You sound like a disgruntled ex-employee or existing, but very out of touch, current employee.
Perhaps you can give us some background as to why you claim such "insight" into how the company should be run, and why we should pay any attention to your opinion
I will let you buy the FLDM
I will let you buy the FLDM stocks. I will pass.
Here's a little reality for
Here's a little reality for you. Its 2013, companies aren't worth very much anymore, they cannot create growth and most are now worth more in pieces than as a chinese buffet. Thermo will be a great example of that in 5 years.
Yes, but their CEO can do
Yes, but their CEO can do magic with investors. Who needs a real product when you can buy scientists to get good reviews and off load the company to BD for 400 million. Buy their stock while you still can.
FLDM's problem is at its core
FLDM's problem is at its core technology: PDMS valve. It can only go that far. Fluidigm opens lots of new fields, yet its technology cannot achieve what it promises.
Everytime they grow, they
Everytime they grow, they also loose a ton. This pig has had expensive lipstick for what ? Ten years? Ten years and still in he red ? Come on now.
Yes, but what if they grow
Yes, but what if they grow 25% in revenue again with like 70% margin?
they got downgraded today, it
they got downgraded today, it appears no one gives a shit about a 200K camera stand over a cheap PCR heating plate.
Nice massive stock drop
Nice massive stock drop today... great timing, looks like more money spend and more money made... Its pretty simple, pcr, single cell, heading towards the commodity market...
Maybe BD will buy them for a
Maybe BD will buy them for a premium!
Sell it to someone who can't
Sell it to someone who can't tell the difference between revenue and profits already!
Haha ha fluidigm. Make more
Haha ha fluidigm. Make more to lose more money. I think it's obvious this dog will never have its head above the water. Gajus can't wait to get back to Alaska so he can come up with more fake shit.
When will they announce their
When will they announce their new CEO?
I can tell you how awful it
I can tell you how awful it is working for Fluidigm. Our marketing team is rude and arrogant!
Of course it is, it is a marketing department. You probably missed out clueless as well though.
O.K, next prediction;
O.K, next prediction; Fluidigm will try very hard to to get bought out by BD. Go GW! Settle for nothing below $400mil. Just focus on the clueless executives and it should be easy to convince them. We paid $200 mil for our last big acquisition and its doing great at becoming the leading loss center, so adding Fluidigm too our portfolio is the next logical step.
I can tell you how awful it
I can tell you how awful it is working for Fluidigm. Our marketing team is rude and arrogant!
All Fluidigm has is sales and
All Fluidigm has is sales and marketing bling. If there sales suck, not much is left.
Well as a customer, their
Well as a customer, their sales people suck. They have no idea on how to support their customers. On the other hand, we've actually really liked the instrument and have been generating good data like crazy.
I think Fluidigm should get
I think Fluidigm should get an award for raising Capitol. I don't know of any organization which has been as successful.
I think GW gets ideas from
I think GW gets ideas from SQ.FLDM is doing much better than PACB,even though the stock is kind of dead money.
They will be bought out at a
They will be bought out at a premium since becoming a self sustaining and profitable company is clearly not realistic. If anyone can do it is GW.
Yes, you did a nice
Yes, you did a nice prediction!What is the next for FLDM?
Wow, did I call that or what?
Wow, did I call that or what? It just announced second IPO today. GW is a genius at raising capitol, can spin a new story every time, and it never misses. Amazing! Let's wait for some fishing/sailing/bear hunting, in the eye of the storm stories to be announced soon as a press release to follow..
Maybe a second IPO when they
Maybe a second IPO when they run out of cash again at the rate they are piling up losses.
Analyst ranking on Fluidigm
Analyst ranking on Fluidigm following Q2 results:
Leerink Swann - Outperform
Cantor Fitzgerald - Buy
Oppenheimer - Outperform
Piper Jaffray - Overweight
Cowen & Company - Outperform
Q2 showed strong product
Q2 showed strong product revenue growth. Stock up 15 percent just this wee (#13.28 at the beginning and $15.28 at the close of the week.
"Wow, they are the only
"Wow, they are the only growth story, I will but their stock now for sure!"
You need to buy a shit load more NOW !
There is no growth or buzz here... The tech is interesting, its use is not impressive and certainly not the markets they play in. Established and flat.
Good luck, it will be a slow slide.
That and the fact that the
That and the fact that the force is with us. (I wish).
They have so many loans to
They have so many loans to pay back. Stock goes down because the Shylock is the investor and knows.
It's a miracle this place still exists and if the IPO didn't happen we would all be done.
So the stock goes down as a
So the stock goes down as a result of good rating. That seems strange.
Sorry to say but AA is gone
Sorry to say but AA is gone in a year, BMK is only up because there is more feet on the street and acceptance is flat. Are they gonna keep talking about single cell for 3 more years because their pipeline is empty and the BMK is one dinosaur ! You don't have a WW business if you get all wet at 10 million a quarter. Sure the progress is good but the volumes are simply anemic... simple as that.
BTW, following the
BTW, following the announcement of Fluidigm's Q1 2012 earnings results, the analyst ratings on the stock are:
Leerink Swann - outperform
Piper - overwieght
Cowen - outperform
Oppenheimer - outperform
Seems like everyone is recommending to buy, not sell.
BofA doesn't cover Fluidigm
BofA doesn't cover Fluidigm so there is no way for them to downgrade the stock.
The analsyts that currently follow FLDM are Leerink Swann, Cowen and Company, Piper Jaffray and Oppenheimer. Deutsche Bank used to cover the stock, but their entire life science tools team jumped to ISI. They can't pick up coverage for at least 6 months (the law). Deutsche Bank hasn't yet replaced their analyst team.
stock down-graded to sell
stock down-graded to sell today by bank of america
As long as losses increase
As long as losses increase every quarter than only the revenue growth should matter. I wonder if there are other ways to further increase revenue/ losses. That would really be in the best interest of shareholders.
Don't go there... not prime
Don't go there... not prime time.
Anyone committed to using
Anyone committed to using their reusable products? Hoping to get some user feedback.
Wow, they are the only growth
Wow, they are the only growth story, I will but their stock now for sure!
Has Fluidigm had a profitable
Has Fluidigm had a profitable quarter yet? They have been around for almost 13 years, so if they are "growing into a real company with a viable long term future", then they need to hit profitability.
I don't feel it, not enough
I don't feel it, not enough Star Wars example.
Are you Mr. Gajus V.
Are you Mr. Gajus V. Worthington?
Fluidigm is the only growth
Fluidigm is the only growth story in life science tools right now. By far the best life science IPO of 2011. Beat the Street estimates every quarter since they became a public company. Looking at their comparables, they are roughly flat while others are minus 30-40 percent. Look back over the string of messages here and see if any of the negatives spewed here have any truth as time has passed. None of the negatives have happened. Fluidigm is growing into a real company with a viable long term future.
unlikely even a low dollar
unlikely even a low dollar will make a difference
Sales should go well with the
Sales should go well with the low $!
How is Fluidigm doing now?
How is Fluidigm doing now? any insight.
SQ = Dr. Quack
SQ = Dr. Quack
One question, when will
One question, when will revenue will be higher than expenses? SQ is still academia, is he one of the 2 you think of? Sounds like MU writting to me.
You are invited to disclose
You are invited to disclose such information about yourself first as you clearly have more inside information and greater operational insight ...
"Very true, but if that's the
"Very true, but if that's the case they need to lean-out operations to show profitability on just the life sci biz. No reason they shouldn't have been running in the black for the past 2 years.
Inexperienced CEO has no true operations experience. BJ/RR care only for themselves. MU/AB have been truly brilliant at creating a toxic culture.
All should move aside and let the grownups make the company a real success before time renders them irrelevant."
You speak as though you know what's going on, yet clearly have no idea of what it actually takes to run a business like this, nor any concept of how much money it takes. Any further "lean-out" of operations would render the company non-functional, although there are still one or two pseudo-academics (perhaps you are one) that should be axed. the company has a long way to go, but makes great products and has finally started to generate significant revenue.
You sound like a disgruntled ex-employee or existing, but very out of touch, current employee.
Perhaps you can give us some background as to why you claim such "insight" into how the company should be run, and why we should pay any attention to your opinion
40 pesos pershare perhaps.
40 pesos pershare perhaps.
cool, $40/share
cool, $40/share
Post new comment